Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Africa Gazette.
Press releases published on April 24, 2025
NevGold Discovers More Significant Oxide Gold-Antimony Results: 2.11 g/t AuEq Over 67.1 Meters (1.30 g/t Au And 0.18% Antimony), Including 4.29 g/t AuEq Over 30.5 Meters (2.79 g/t Au And 0.33% Antimony), and Also Including 7.12 g/t AuEq Over 16.8…
GlobeNewswire
·
April 24, 2025
Vancouver, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has discovered further significant oxide gold-antimony (“Antimony”, “Sb”) …
Fulcrum Therapeutics to Host First Quarter 2025 Financial Results Conference Call and Webcast on Thursday, May 1, 2025, at 8:00 a.m. ET
GlobeNewswire
·
April 24, 2025
CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare …
ORYZON Raises €30 Million in Capital Increase
GlobeNewswire
·
April 24, 2025
Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US institutional investor Proceeds to fund …
Ace Vision Group Announces Initial Close of $29.4 Million Series B Financing Round
GlobeNewswire
·
April 24, 2025
Funding supports the commercial product development of VisioLite® Device and Laser Scleral Microporation Human Clinical Study. Capital raised to date provides strong financial position to prepare the device for regulatory trials and submissions. BOSTON, …
Avidicure Launches with $50 Million in Seed Financing to Develop New Multifunctional Antibody Modality to Treat Cancer
GlobeNewswire
·
April 24, 2025
AVC-Boosters are designed as dual agonistic antibodies to safely deliver targeted and potent monotherapy with broad application in oncology Lead product AVC-S-101 is a TROP2-targeting booster being developed for non-small cell lung cancer and multiple …
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire
·
April 24, 2025
JUPITER, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report first quarter 2025 financial results before the opening of the U.S. financial markets on Thursday, May 8, 2025. The …
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
GlobeNewswire
·
April 24, 2025
SAN JOSE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited …
Brunswick Exploration Drills 36 Meters at 1.51% and Continues to Extend the Mineralized Footprint of Mirage
GlobeNewswire
·
April 24, 2025
MONTREAL, April 24, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to report the first results from the 2025 Mirage winter drilling campaign where it drilled an additional twenty-four holes …
Stallion Uranium Closes $1.45 million Private Placement
GlobeNewswire
·
April 24, 2025
VANCOUVER, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) -- Stallion Uranium Corp. (the “Company” or “Stallion”) (TSX-V: STUD; OTCQB: STLNF; FSE: FE0) is pleased to announce that, further to its news releases dated April 1, 2025 and April 8, 2025, it …
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
GlobeNewswire
·
April 24, 2025
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9), a clinical-stage biotechnology company advancing a …
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
GlobeNewswire
·
April 24, 2025
For immediate release iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP reduction sustained Over 5000 patients …
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2025
GlobeNewswire
·
April 24, 2025
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including …